Gene expression pathways of high grade localized prostate cancer

Despite advances in screening and local therapy, prostate cancer remains the second most common cause of cancer related death among American men, with those having high grade disease being at highest risk for prostate cancer mortality. Here we identify the genes and cellular pathways that distinguish high grade from low grade pathologically localized prostate cancer.

[1]  L. Marchionni,et al.  Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity , 2011, BJU international.

[2]  H. Wu,et al.  NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response , 2011, Oncogene.

[3]  Y. Huang,et al.  Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells , 2010, Oncogene.

[4]  M. Gleave,et al.  Multimodal approaches to high-risk prostate cancer. , 2010, Current oncology.

[5]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[6]  A. Partin,et al.  Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. , 2010, Urology.

[7]  Gabriela Kalna,et al.  Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. , 2010, The Journal of clinical investigation.

[8]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[9]  E. Hurt,et al.  Genomic profiling of tumor initiating prostatospheres , 2010, BMC Genomics.

[10]  E. Antonarakis,et al.  Novel targeted therapeutics for metastatic castration-resistant prostate cancer. , 2010, Cancer letters.

[11]  P. Crooks,et al.  A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. , 2010, Cancer research.

[12]  G. Sykiotis,et al.  Stress-Activated Cap'n'collar Transcription Factors in Aging and Human Disease , 2010, Science Signaling.

[13]  Hailong Wu,et al.  Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth , 2010, Molecular Cancer Therapeutics.

[14]  A. Poustka,et al.  Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low- and high-risk prostate cancer , 2009, Molecular Cancer.

[15]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[16]  C. Bousquet,et al.  4E‐BP1 is a target of Smad4 essential for TGFβ‐mediated inhibition of cell proliferation , 2009, The EMBO journal.

[17]  T. Dang,et al.  Notch3 Cooperates With the EGFR Pathway to Modulate Apoptosis Through The Induction Of Bim , 2009, Oncogene.

[18]  Andrew J Vickers,et al.  Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Nugent,et al.  Lysyl Oxidase Pro-peptide Inhibits Prostate Cancer Cell Growth by Mechanisms that Target FGF-2-Cell Binding and Signaling , 2009, Oncogene.

[20]  P. Casey,et al.  Activation of Rap1 promotes prostate cancer metastasis. , 2009, Cancer research.

[21]  J. Deddens,et al.  eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. , 2009, Cancer research.

[22]  H. Kroemer,et al.  Expression of ABCC-Type Nucleotide Exporters in Blasts of Adult Acute Myeloid Leukemia: Relation to Long-term Survival , 2009, Clinical Cancer Research.

[23]  Hiroshi Handa,et al.  A general mechanism for transcription regulation by Oct1 and Oct4 in response to genotoxic and oxidative stress. , 2009, Genes & development.

[24]  G Parmigiani,et al.  Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer , 2008, Oncogene.

[25]  J. Simon,et al.  Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.

[26]  K. Jauch,et al.  Cancer stem cells: how can we target them? , 2008, Current medicinal chemistry.

[27]  Uwe Zimmermann,et al.  Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells , 2008, The FEBS journal.

[28]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[29]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[30]  Dirk F Moore,et al.  Survival following primary androgen deprivation therapy among men with localized prostate cancer. , 2008, JAMA.

[31]  B. Fraile,et al.  TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate. , 2008, Histology and histopathology.

[32]  K. Pienta,et al.  The Role of CXCR7/RDC1 as a Chemokine Receptor for CXCL12/SDF-1 in Prostate Cancer* , 2008, Journal of Biological Chemistry.

[33]  K. Coombes,et al.  Biomarker expression patterns that correlate with high grade features in treatment naive, organ-confined prostate cancer. , 2008 .

[34]  A. Haese*,et al.  Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer , 2007, Clinical Cancer Research.

[35]  F. Marshall,et al.  PrLZ Is Expressed in Normal Prostate Development and in Human Prostate Cancer Progression , 2007, Clinical Cancer Research.

[36]  L. Chung,et al.  PC-1/PrLZ contributes to malignant progression in prostate cancer. , 2007, Cancer research.

[37]  Kalyani V. P. Guntur,et al.  Tumor Necrosis Factor α (TNFα) Stimulates Map4k4 Expression through TNFα Receptor 1 Signaling to c-Jun and Activating Transcription Factor 2* , 2007, Journal of Biological Chemistry.

[38]  J. Wang-Rodriguez,et al.  Expression signatures that correlated with Gleason score and relapse in prostate cancer. , 2007, Genomics.

[39]  Yusuke Nakamura,et al.  Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. , 2007, Cancer research.

[40]  M. Ittmann,et al.  Relaxin Promotes Prostate Cancer Progression , 2007, Clinical Cancer Research.

[41]  Zhe-Sheng Chen,et al.  ABCC10, ABCC11, and ABCC12 , 2007, Pflügers Archiv - European Journal of Physiology.

[42]  Leroy Hood,et al.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Jason A. Koutcher,et al.  Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.

[44]  Yingyao Zhou,et al.  A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Hagemann,et al.  The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. , 2005, Cancer research.

[46]  T. Wheeler,et al.  Pim‐2 upregulation: Biological implications associated with disease progression and perinueral invasion in prostate cancer , 2005, The Prostate.

[47]  C. Tseng,et al.  The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. , 2005, Cancer research.

[48]  C. Tseng,et al.  Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor. , 2005, Cancer research.

[49]  R. Ball,et al.  Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues , 2005, British Journal of Cancer.

[50]  John Quackenbush,et al.  Multiple-laboratory comparison of microarray platforms , 2005, Nature Methods.

[51]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[52]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[53]  J. Grootegoed,et al.  EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2 , 2005, International journal of cancer.

[54]  F. Marshall,et al.  Loss of HOXC6 expression induces apoptosis in prostate cancer cells , 2005, Oncogene.

[55]  M. Cooperberg,et al.  The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. , 2004, The Journal of urology.

[56]  James R Lambert,et al.  Aberrant HOXC expression accompanies the malignant phenotype in human prostate. , 2003, Cancer research.

[57]  J. Grootegoed,et al.  REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells , 2003, Oncogene.

[58]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[59]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[60]  D. Theodorescu,et al.  The role of Ral A in epidermal growth factor receptor-regulated cell motility. , 2002, Cancer research.

[61]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[62]  T. Wheeler,et al.  Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. , 1998, Cancer research.

[63]  S. Sheng,et al.  Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4 , 1997, Oncogene.

[64]  Kalyani V. P. Guntur,et al.  Tumor necrosis factor alpha (TNFalpha) stimulates Map4k4 expression through TNFalpha receptor 1 signaling to c-Jun and activating transcription factor 2. , 2007, The Journal of biological chemistry.

[65]  John T. Wei,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.

[66]  R. Kane,et al.  The results of a five‐year early prostate cancer detection intervention , 1996, Cancer.

[67]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.